Shenzhen Bay Laboratory has synthesized fused ring derivatives acting as dihydrofolate reductase (DHFR) (bacterial) inhibitors reported to be useful for the treatment of cancer, bacterial, fungal, nematode and viral infections.
Pfizer Inc. has identified new indole analogues acting as sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease (NAFLD; MASLD), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism-spectrum disorders, among others.
Merck Sharp & Dohme LLC (MSD) has synthesized new N-oxide derivative targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of HIV infection.
Northern Illinois University and Stream Neuroscience Inc. have patented benzothiazole derivatives acting as phosphodiesterase‑4 (PDE4) inhibitors and reported to be useful for the treatment of cancer, cognitive, inflammatory and mood disorders.
Simcere Zaiming Pharmaceutical Co. Ltd. has described membrane‑associated tyrosine‑ and threonine‑specific Cdc2‑inhibitory kinase (PKMYT1) inhibitors for cancer.
Washington University in St. Louis has disclosed new autophagy inducers reported to be useful for the treatment of alpha-1 antitrypsin deficiency, amyotrophic lateral sclerosis, Alzheimer’s, Huntington’s and Parkinson’s disease.
Domain Therapeutics SA has prepared and tested new azine-based compounds acting as proteinase-activated receptor 2 (F2RL1; PAR2) inhibitors reported to be useful for the treatment of allergy, autoimmune, metabolic diseases, cardiovascular, dermatological, inflammatory disorders, pain and cancer.
RSS